| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| DEFA14A | Additional proxy soliciting materials - definitive |
Proxy Filings
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| 8-K/A | Amendment to a previously filed 8-K |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
| DFAN14A | Additional proxy soliciting materials filed by non-management |
Proxy Filings
|
||
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
